Investment
Features
FeesSafety
Academy
More
Pluang+

Ero Copper rated Buy with 42% upside as production set to rise by a third by 2028.

Analyst Insights
18 Sep 2026
Seeking Alpha
View Source
Bullish
Ero Copper rated Buy with 42% upside as production set to rise by a third by 2028.

Ero Copper (ERO) is rated Buy with a $50 price target, implying a 42% upside driven by a projected one-third increase in copper production by 2028. The stock trades at a forward EV/EBITDA of 5.74x, below historical and sector averages, supported by near-completion of capital expenditures and reduced leverage to 0.8x. Key risks include potential delays in the Caraíba shaft completion, which could delay growth and affect valuation. Upcoming catalysts include Capital Markets Day, shareholder return updates, shaft progress reports, and an updated Tucumã reserve report.

Ero Copper's growth outlook is highlighted by a 42% upside price target amid a projected one-third increase in copper production by 2028. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Sep 18, 2026 19:13 WIB: Of 34 priced US Basic Materials stocks, 20 rose and 13 fell. Notable movers include Agnico Eagle Mines Ltd (AEM) at USD 202.90 with 0% Sell / 100% Buy order activity, Wheaton Precious Metals Corp (WPM) at USD 153.33 also with 0% Sell / 100% Buy, and Barrick Gold Corp (B) at USD 43.97 with 87% Sell / 13% Buy.

More News

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
28 minutes ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
43 minutes ago
Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim has raised its price target for Restaurant Brands International (QSR) to $86 from $85 and reiterated a Buy rating, reflecting confidence in the company's strategic growth. Restaurant Brands International is enhancing shareholder value thro...

Analyst Insights
Bullish
2 hours ago
SpaceX shares rise 8% on strong revenue growth despite $541M loss, with mixed analyst views on future momentum.

SpaceX shares rise 8% on strong revenue growth despite $541M loss, with mixed analyst views on future momentum.

SpaceX's stock climbed 8% recently after reporting a 92% revenue increase to $7.81 billion, driven by Starlink and AI growth, but also posted a $541 million quarterly loss. The company aims for $100 billion annual revenue by year-end and a trillion-d...

Market News
Neutral
4 hours ago
Oracle stock halves despite booming AI backlog, with a 55% upside forecast amid mixed cash flow signals.

Oracle stock halves despite booming AI backlog, with a 55% upside forecast amid mixed cash flow signals.

Oracle's stock has dropped 53% over the past year to around $140, even as its AI-related backlog surged to $664 billion, raising questions about market valuation. The company reported strong Q1 FY2027 results, including 29.6% revenue growth and a 121...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App